Breyanzi Approved as Second-Line Treatment for Large B-Cell Lymphoma
The expanded approval was based on data from the phase 3 TRANSFORM and phase 2 PILOT studies.
Diagnosis & Disease Information
Fever of Unknown Origin Features Later Diagnosed as Lymphoma
Researchers sought to define clinical and prognostic features associated with fever of unknown origin in patients later diagnosed with lymphoma.
Kymriah Gets Accelerated Approval for Relapsed/Refractory Follicular Lymphoma
The accelerated approval for Kymriah was based on data from the phase 2 ELARA trial.
Phthalates in Medications May Increase Risk of Childhood Cancers
Children prescribed a medication containing a phthalate had a 19% higher risk of developing any childhood cancer.
Heart Failure Tied to Increased Risk of Cancers, Cancer-Related Mortality
The excess risk of cancer appeared to be associated with the severity of heart failure.
Some Immune-Mediated Diseases May Increase Cancer Risk
The risk of developing any cancer was significantly higher among patients with immune-mediated diseases.
Copiktra Indication for Relapsed/Refractory Follicular Lymphoma Withdrawn
The Company will be working with the FDA in the coming weeks to complete the label revision process.
Breakthrough COVID-19 May Be More Common in Patients With Lymphoid Malignancies
About 81% of patients had lymphoproliferative malignancies.
Parsaclisib Under Review for Follicular, Marginal Zone, and Mantle Cell Lymphomas
The application is supported by data from several phase 2 studies.
Survey Reveals ‘Striking’ Barriers to Accessing High-Priority Cancer Drugs
Respondents said some essential cancer drugs had substantial out-of-pocket costs, and some posed a high risk of catastrophic expenditure.
- Loading...
Loading...
Loading... 
Loading...